Yuanmei Zhu

6PUBLICATIONS
5CO-AUTHORS
Medical devicesMolecular targetsGene and molecular therapyProteins and peptidesVeterinary virology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|Sep 08, 2026
The α-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.

|Jul 05, 2022
SARS-CoV-2 fusion-inhibitory lipopeptides maintain high potency against divergent variants of concern including Omicron.

Yuanmei Zhu, Xiaojing Dong, Nian Liu

|Nov 25, 2021
Cell membrane-anchored anti-HIV single-chain antibodies and bifunctional inhibitors targeting the gp41 fusion protein: new strategies for HIV gene therapy.

Yue Chen, Hongliang Jin, Xiaoran Tang

|May 31, 2021
Structure-based design and characterization of novel fusion-inhibitory lipopeptides against SARS-CoV-2 and emerging variants.

Danwei Yu, Yuanmei Zhu, Tao Jiao

|Apr 13, 2021
Pan-coronavirus fusion inhibitors possess potent inhibitory activity against HIV-1, HIV-2, and simian immunodeficiency virus.

Danwei Yu, Yuanmei Zhu, Hongxia Yan

|Oct 10, 2020
Cross-reactive neutralization of SARS-CoV-2 by serum antibodies from recovered SARS patients and immunized animals.

Yuanmei Zhu, Danwei Yu, Yang Han

Pageof 1

Frequent Collaborators

3 joint publications

Jianwei Wang

2 joint publications

Yuxian He

1 joint publications

Danwei Yu

1 joint publications

Yang Han